- Conditions
- Persistent Corneal Epithelial Defect
- Interventions
- lufepirsen high dose, Vehicle, lufepirsen low dose
- Drug
- Lead sponsor
- Glaukos Corporation
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 21
- States / cities
- Dothan, Alabama • Petaluma, California • Torrance, California + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Persistent Corneal Epithelial Defect
- Interventions
- ST266, 0.67% Sodium Chloride Ophthalmic Solution, Open-label ST266
- Biological · Other
- Lead sponsor
- Noveome Biotherapeutics, formerly Stemnion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 31
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Huntington Beach, California + 23 more
- Conditions
- Persistent Corneal Epithelial Defect
- Interventions
- TP-06, Vehicle of TP-06
- Drug
- Lead sponsor
- Tarsus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Tampa, Florida • Atlanta, Georgia + 7 more
- Conditions
- Corneal Persistent Epithelial Defect
- Interventions
- Nexagon® (lufepirsen) High Dose Concentration, Nexagon® (lufepirsen) Low Dose Concentration, Vehicle, Open-label Nexagon® (lufepirsen)
- Drug
- Lead sponsor
- Glaukos Corporation
- Industry
- Eligibility
- Not listed
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Persistent Corneal Epithelial Defect
- Interventions
- Cenegermin, Vehicle
- Drug · Other
- Lead sponsor
- Dompé Farmaceutici S.p.A
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 18
- States / cities
- Huntington Beach, California • Laguna Hills, California • Loma Linda, California + 14 more
- Conditions
- Cornea
- Interventions
- carboxymethylcellulose sodium, Acuvue Oasys Bandage Contact Lens, Ambiodisk, Prokera
- Drug · Device
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Persistent Corneal Epithelial Defect
- Interventions
- KPI-012, KPI-012 Vehicle
- Drug
- Lead sponsor
- Combangio, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 43
- States / cities
- Dothan, Alabama • Irvine, California • La Jolla, California + 35 more
- Conditions
- Persistent Corneal Epithelial Defect, Corneal Epithelial Disorders
- Interventions
- Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome, Vehicle Control
- Drug · Other
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Neurotrophic Keratitis
- Interventions
- KB801, Placebo
- Biological · Drug
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 9
- States / cities
- Irvine, California • Pasadena, California • Carmel, Indiana + 6 more
- Conditions
- Persistent Corneal Epithelial Defect
- Interventions
- ST266
- Biological
- Lead sponsor
- Noveome Biotherapeutics, formerly Stemnion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 8
- States / cities
- Indianapolis, Indiana • Edgewood, Kentucky • Baltimore, Maryland + 5 more